Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 31 min ago
Peer-reviewedCC BYGenes

Diagnostic and Clinical Considerations in Myeloid Neoplasms with del(5q): Distinguishing Myelodysplastic Neoplasm with Low Blasts and del(5q) from Myeloid Neoplasms with del(5q) Post-Cytotoxic Therapy

  • Changqing Xia1
  • Zhenya Tang1
  • Shanxiang Zhang1
  • Allison Cushman-Vokoun1
  • Krishna Gundabolu2
  • Michael Haddadin2
  • Joseph D. Khoury1
  1. 1Department of Pathology, Microbiology and Immunology, , 42nd Street & Emile Street, Omaha, NE 68198, USA; (Z.T.); (S.Z.); (A.C.-V.); (J.D.K.)
  2. 2Division of Hematology, Department of Internal Medicine, , Omaha, NE 68198, USA; (K.G.); (M.H.)
Read full textPDFCite

Related

  1. Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
    Valérie Bardet, Wagner-Ballon O, Guy J +12
    HaematologicaPeer-reviewedLicence not statedFull text43 citedGeneral biologyGeneral medicineHAL
  2. GENOME-WIDE COPY NUMBER VARIATIONS REVEAL DISTINCT GENOMIC SIGNATURES IN AN ADMIXED BRAZILIAN COHORT WITH MYELODYSPLASTIC NEOPLASMS
    João Vitor Caetano GOES, Letícia Rodrigues SAMPAIO, Rodrigo CAVAGNA +7
    Hematology, Transfusion and Cell TherapyPeer-reviewedCC BYFull textGenetics & genomicsDOAJ
  3. Diagnostic pitfalls and unmet needs in neuroendocrine neoplasms: The added value of collegial expert pathology review through the national TENpath network
    Matthieu Tihy, Jean-Yves Scoazec, Serge Guyétant +30
    European Journal of CancerPeer-reviewedCC BY 4.0Full textGeneral biologyOncologyHAL
  4. Concurrent Loss of PIGA and ZRSR2 in a Patient With Paroxysmal Nocturnal Hemoglobinuria and Myelodysplastic Neoplasm
    Fatma AlBulushi, Eric McGinnis
    International Journal of Laboratory HematologyPeer-reviewedCC BY 4.0Full textImmunologyPMC
  5. The fraction of CD117/c-KIT-expressing erythroid precursors predicts ESA response in low-risk myelodysplastic syndromes.
    Raimbault A, Itzykson R, Willems L +9
    Cytometry. Part B, Clinical cytometryPeer-reviewedLicence not statedFull text16 citedGeneral biologyGeneral medicineHAL

Cite

BibTeXRIS
BibTeX
@article{xia2026diagnostic,
  title = {{Diagnostic and Clinical Considerations in Myeloid Neoplasms with del(5q): Distinguishing Myelodysplastic Neoplasm with Low Blasts and del(5q) from Myeloid Neoplasms with del(5q) Post-Cytotoxic Therapy}},
  author = {Changqing Xia and Zhenya Tang and Shanxiang Zhang and Allison Cushman-Vokoun and Krishna Gundabolu and Michael Haddadin and Joseph D. Khoury},
  journal = {Genes},
  year = {2026},
  month = oct,
  url = {https://europepmc.org/article/PMC/PMC13704666},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Diagnostic and Clinical Considerations in Myeloid Neoplasms with del(5q): Distinguishing Myelodysplastic Neoplasm with Low Blasts and del(5q) from Myeloid Neoplasms with del(5q) Post-Cytotoxic Therapy
AU  - Changqing Xia
AU  - Zhenya Tang
AU  - Shanxiang Zhang
AU  - Allison Cushman-Vokoun
AU  - Krishna Gundabolu
AU  - Michael Haddadin
AU  - Joseph D. Khoury
PY  - 2026
DA  - 2026/10/01
JO  - Genes
UR  - https://europepmc.org/article/PMC/PMC13704666
SN  - 2073-4425
ER  -